Resveratrol intake during pregnancy and lactation re-programs adiposity and ameliorates leptin resistance in male progeny induced by maternal high-fat/high sucrose plus postnatal high-fat/high sucrose diets via fat metabolism regulation.
Adiposity
/ drug effects
Analysis of Variance
Animals
Blotting, Western
Body Weight
/ drug effects
Diet, High-Fat
/ adverse effects
Eating
/ drug effects
Female
Lactation
/ drug effects
Lipid Metabolism
/ drug effects
Lipogenesis
/ drug effects
Lipolysis
/ drug effects
Male
Obesity
/ metabolism
Rats
Rats, Sprague-Dawley
Resveratrol
/ pharmacology
Reverse Transcriptase Polymerase Chain Reaction
Sirtuin 1
/ metabolism
Adiposity
High-fat diet
Leptin
Maternal resveratrol
Postnatal
Prenatal
Reprograms
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
25 Jul 2020
25 Jul 2020
Historique:
received:
06
05
2020
accepted:
14
07
2020
entrez:
27
7
2020
pubmed:
28
7
2020
medline:
8
6
2021
Statut:
epublish
Résumé
Maternal obesity is an emerging problem in the modern world. Growing evidence suggests that intrauterine high-fat (HF) exposure may predispose progeny to subsequent metabolic challenges. Progeny born to mothers who ate an HF diet also tends to eat an HF diet when growing and aggravate metabolic issues. Thus, the generational transmission of obesity is cyclical. Developing a strategy to prevent the occurrence of metabolic syndrome related to prenatal and/or postnatal HF diet is important. In this study, the reprogramming effects of maternal resveratrol treatment for the progeny with maternal HF/postnatal HF diets were investigated. Sprague-Dawley dams were fed either a control or a high-fat/high sucrose diet (HFHS) from mating to lactation. After weaning, the progeny was fed chow or an HF diet. Four experimental groups were yielded: CC (maternal/postnatal control diet), HC (maternal HF/postnatal control diet), CH (maternal control/postnatal HFHS diet), and HH (maternal/postnatal HFHS diet). A fifth group (HRH) received a maternal HFHS diet plus maternal resveratrol treatment and a postnatal chow diet to study the effects of maternal resveratrol therapy. Maternal resveratrol treatment lessened the weight and adiposity of progeny that were programmed by combined prenatal and postnatal HFHS diets. Maternal resveratrol therapy ameliorated the decreased abundance of the sirtuin 1 (SIRT1) enzyme in retroperitoneal tissue and the altered leptin/soluble leptin receptor ratio of progeny. Maternal resveratrol therapy also decreased lipogenesis and increased lipolysis for progeny. Maternal resveratrol intervention can prevent adiposity programmed by maternal and postnatal HFHS diets by inducing lipid metabolic modulation. This study offers a novel reprogramming role for the effect of maternal resveratrol supplements against obesity.
Sections du résumé
BACKGROUND
BACKGROUND
Maternal obesity is an emerging problem in the modern world. Growing evidence suggests that intrauterine high-fat (HF) exposure may predispose progeny to subsequent metabolic challenges. Progeny born to mothers who ate an HF diet also tends to eat an HF diet when growing and aggravate metabolic issues. Thus, the generational transmission of obesity is cyclical. Developing a strategy to prevent the occurrence of metabolic syndrome related to prenatal and/or postnatal HF diet is important. In this study, the reprogramming effects of maternal resveratrol treatment for the progeny with maternal HF/postnatal HF diets were investigated.
METHODS
METHODS
Sprague-Dawley dams were fed either a control or a high-fat/high sucrose diet (HFHS) from mating to lactation. After weaning, the progeny was fed chow or an HF diet. Four experimental groups were yielded: CC (maternal/postnatal control diet), HC (maternal HF/postnatal control diet), CH (maternal control/postnatal HFHS diet), and HH (maternal/postnatal HFHS diet). A fifth group (HRH) received a maternal HFHS diet plus maternal resveratrol treatment and a postnatal chow diet to study the effects of maternal resveratrol therapy.
RESULTS
RESULTS
Maternal resveratrol treatment lessened the weight and adiposity of progeny that were programmed by combined prenatal and postnatal HFHS diets. Maternal resveratrol therapy ameliorated the decreased abundance of the sirtuin 1 (SIRT1) enzyme in retroperitoneal tissue and the altered leptin/soluble leptin receptor ratio of progeny. Maternal resveratrol therapy also decreased lipogenesis and increased lipolysis for progeny.
CONCLUSIONS
CONCLUSIONS
Maternal resveratrol intervention can prevent adiposity programmed by maternal and postnatal HFHS diets by inducing lipid metabolic modulation. This study offers a novel reprogramming role for the effect of maternal resveratrol supplements against obesity.
Identifiants
pubmed: 32711539
doi: 10.1186/s12944-020-01349-w
pii: 10.1186/s12944-020-01349-w
pmc: PMC7382831
doi:
Substances chimiques
Sirtuin 1
EC 3.5.1.-
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174Subventions
Organisme : Chang Gung Memorial Hospital
ID : CMRPG8G0642 and 8J0871
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 107-2314-B-182 -044 -MY2
Références
Nutrients. 2019 Aug 07;11(8):
pubmed: 31394876
Horm Metab Res. 2010 Jul;42(8):585-9
pubmed: 20455195
J Physiol. 2017 Mar 1;595(5):1547-1562
pubmed: 27891610
Am J Obstet Gynecol. 2014 Sep;211(3):237.e1-237.e13
pubmed: 24631702
Int J Mol Sci. 2019 Mar 06;20(5):
pubmed: 30845644
J Clin Endocrinol Metab. 2002 Apr;87(4):1708-16
pubmed: 11932305
Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):729-36
pubmed: 20823772
Ann Intern Med. 2014 Apr 1;160(7):515-6
pubmed: 24687079
Clin Interv Aging. 2013;8:829-44
pubmed: 23869170
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1232-8
pubmed: 16920065
J Obes. 2016;2016:8375828
pubmed: 28050279
Nutrients. 2020 Apr 12;12(4):
pubmed: 32290535
J Physiol. 2019 Aug;597(16):4175-4192
pubmed: 31240717
J Nutr. 2002 Feb;132(2):257-60
pubmed: 11823587
Nat Commun. 2019 Oct 22;10(1):4799
pubmed: 31641124
J Neurosci Res. 2018 Oct;96(10):1641-1662
pubmed: 30098077
Diabetes Care. 1998 Dec;21 Suppl 3:C11-4
pubmed: 9850480
Int J Mol Sci. 2018 Aug 31;19(9):
pubmed: 30200293
Diabetes. 1998 Feb;47(2):230-8
pubmed: 9519718
Ann N Y Acad Sci. 2009 Sep;1173 Suppl 1:E10-9
pubmed: 19751409
Front Endocrinol (Lausanne). 2016 Jun 27;7:73
pubmed: 27445976
J Neurosci. 2008 Nov 12;28(46):12107-19
pubmed: 19005075
Ann Intern Med. 2016 Mar 1;164(5):305-12
pubmed: 26857595
J Nutr Biochem. 2020 Jan;75:108260
pubmed: 31707285
J Physiol Pharmacol. 2003 Dec;54(4):469-87
pubmed: 14726604
Oncotarget. 2017 Dec 6;8(67):111998-112013
pubmed: 29340106
J Acad Nutr Diet. 2014 Jul;114(7):1099-103
pubmed: 24956993
Semin Reprod Med. 2009 Sep;27(5):358-68
pubmed: 19711246
FASEB J. 1998 Jan;12(1):57-65
pubmed: 9438411
Int J Mol Sci. 2020 May 12;21(10):
pubmed: 32408716
Biochem Biophys Res Commun. 2010 Mar 26;394(1):24-8
pubmed: 20170634
J Neurosci Res. 2019 Jun;97(6):708-726
pubmed: 30742328
Arch Med Res. 2020 Feb;51(2):105-114
pubmed: 32111491
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
pubmed: 16732220
Ageing Res Rev. 2018 Mar;42:40-55
pubmed: 29248758
Nutrition. 2016 Feb;32(2):174-8
pubmed: 26706021
Lipids Health Dis. 2018 Mar 14;17(1):50
pubmed: 29540174
Biosci Rep. 2018 Mar 9;38(2):
pubmed: 29437902
Exp Ther Med. 2016 Mar;11(3):753-762
pubmed: 26997989
J Dev Orig Health Dis. 2015 Apr;6(2):55-64
pubmed: 25471238
World J Diabetes. 2017 Sep 15;8(9):422-428
pubmed: 28989568
Pharmacol Res. 2010 Jul;62(1):35-41
pubmed: 20026274
Endocr Rev. 2007 Dec;28(7):763-77
pubmed: 17981890
BMJ. 1991 Oct 26;303(6809):1019-22
pubmed: 1954451
Immun Ageing. 2018 Feb 14;15:8
pubmed: 29456585
N Engl J Med. 2005 Mar 17;352(11):1138-45
pubmed: 15784668
Nature. 2006 Nov 16;444(7117):337-42
pubmed: 17086191
Obes Res. 2003 Jun;11(6):760-8
pubmed: 12805397
J Sci Food Agric. 2018 Mar;98(5):1757-1764
pubmed: 28862329
J Matern Fetal Neonatal Med. 2019 Sep;32(17):2943-2949
pubmed: 29562760
Curr Genomics. 2019 Sep;20(6):419-427
pubmed: 32476999
N Engl J Med. 2005 Oct 27;353(17):1848-50
pubmed: 16251542
Mol Nutr Food Res. 2019 Apr 20;:e1801385
pubmed: 31004461
Diabetes Care. 1998 Apr;21(4):518-24
pubmed: 9571335
J Endocrinol Invest. 2017 Sep;40(9):899-909
pubmed: 28283913
PLoS One. 2014 Nov 17;9(11):e112355
pubmed: 25401949
Indian J Exp Biol. 2012 Nov;50(11):802-9
pubmed: 23305031
Front Physiol. 2013 Feb 18;4:14
pubmed: 23423541
Tohoku J Exp Med. 2017;241(3):225-237
pubmed: 28344212
World J Nephrol. 2014 Aug 6;3(3):50-63
pubmed: 25332896
Int J Mol Sci. 2016 Sep 22;17(10):
pubmed: 27669212
ILAR J. 2012;53(3-4):306-21
pubmed: 23744969
J Diet Suppl. 2018 May 4;15(3):330-342
pubmed: 28816548
Science. 1995 Jul 28;269(5223):540-3
pubmed: 7624776
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7385-90
pubmed: 9636158
Annu Rev Physiol. 2000;62:413-37
pubmed: 10845097
Biochem Biophys Rep. 2017 Jan 05;9:173-179
pubmed: 28956002
BioDrugs. 2000 Jun;13(6):391-6
pubmed: 18034545